Abstract:After ischaemic cerebral vascular injury, efferocytosis—a process known as the efficient clearance of apoptotic cells (ACs) by various phagocytes in both physiological and pathological states—is crucial for maintaining central nervous system (CNS) homeostasis and regaining prognosis. The mechanisms of efferocytosis in ischaemic stroke and its influence on preventing inflammation progression from secondary injury were still not fully understood, despite the fact that the fundamental process of efferocytosis has been described in a series of phases, including AC recognition, phagocyte engulfment, and subsequent degradation. The genetic reprogramming of macrophages and brain-resident microglia after an ischaemic stroke has been equated by some researchers to that of the peripheral blood and brain. Based on previous studies, some molecules, such as signal transducer and activator of transcription 6 (STAT6), peroxisome proliferator-activated receptor γ (PPARG), CD300A, and sigma non-opioid intracellular receptor 1 (SIGMAR1), were discovered to be largely associated with aspects of apoptotic cell elimination and accompanying neuroinflammation, such as inflammatory cytokine release, phenotype transformation, and suppressing of antigen presentation. Exacerbated stroke outcomes are brought on by defective efferocytosis and improper modulation of pertinent signalling pathways in blood-borne macrophages and brain microglia, which also results in subsequent tissue inflammatory damage. This review focuses on recent researches which contain a number of recently discovered mechanisms, such as studies on the relationship between benign efferocytosis and the regulation of inflammation in ischaemic stroke, the roles of some risk factors in disease progression, and current immune approaches that aim to promote efferocytosis to treat some autoimmune diseases. Understanding these pathways provides insight into novel pathophysiological processes and fresh characteristics, which can be used to build cerebral ischaemia targeting techniques.

Mechanisms of efferocytosis in determining inflammation resolution: Therapeutic potential and the association with cardiovascular disease

Efferocytosis and Its Associated Cytokines: A Light on Non-tumor and Tumor Diseases?

Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies

Emerging Roles of Macrophages in Heart Failure and Associated Treatment Approaches

The role of efferocytosis‐fueled macrophage metabolism in the resolution of inflammation

Mechanism of Efferocytosis in Determining Ischaemic Stroke Resolution—Diving into Microglia/Macrophage Functions and Therapeutic Modality

Potential Mechanisms and Effects of Efferocytosis in Atherosclerosis

Interface between Resolvins and Efferocytosis in Health and Disease

Efferocytosis: Current Status and Future Prospects in the Treatment of Autoimmune Diseases

Efferocytosis: A New Therapeutic Target for Stroke

Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution

The Impaired Mechanism and Facilitated Therapies of Efferocytosis in Atherosclerosis.

Immunomodulation of wound healing leading to efferocytosis

At the heart of inflammation: Unravelling cardiac resident macrophage biology

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Mechanism of efferocytosis in atherosclerosis

Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets

Resveratrol and piceid enhance efferocytosis by increasing the secretion of MFG-E8 in human THP-1 macrophages

Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids

Efferocytosis in lung mucosae: implications for health and disease

Targeting Epigenetic Regulators for Inflammation: Mechanisms and Intervention Therapy